As a DCU spin-out, BioUETIKON had over 10 years' experience of biopharmaceutical production prior to CPH investment in late 2006. This investment allowed the expansion and development of their services and facilities throughout 2007, with the aim of achieving a leading position in development and execution of efficient bioprocessing services.
BioUETIKON
is the first investment in Ireland for CPH. The country was
chosen for the government's approach and commitment to the
pharmaceuticals industry, its market accessibility to Europe and the
USA, skilled workforce and business friendly environment.
Its latest contract with Orthomimetics is to develop a process and produce a regenerative medical device 'scaffold' which will reduce the need for joint replacements. Over 2m people worldwide have joint replacement procedures each year. While joint surgery can be painful and implants have a limited life-span, this new product being produced at the BioUETIKON facility will help surgeons to treat joint injuries more effectively without the need for open surgery. The new product or 'scaffold' has already undergone pre-clinical trials and will go to clinical trial later this year.
According to Managing Director of BioUETIKON, Mike Mulcahy, "Many new treatments for diseases such as cancer, immune diseases and AIDS are being discovered through life science research. These potential treatments need to be developed and manufactured with expertise in 'good manufacturing practice' which includes safety standards and effective production techniques. BioUETIKON has the facilities, as well as the qualified and experienced personnel to convert scientific 'discovery' into commercial supply of drugs, thus taking advantage of the growing multi-million dollars global market in the pharmaceutical industry."
For more information about the event or BioUETIKON, please contact Karen Delaney at +353 1 7007007 or email karen.delaney@biouetikon.com.
